All In Biotech

Drug Trial Radar · NCT06557265

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 13, 2024

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Nkarta, Inc.Industry
Sponsor type
Industry
First posted
Aug 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

Conditions

  • Lupus Nephritis
  • Primary Membranous Nephropathy

Interventions

  • NKX019Drug

    NKX019 is an investigational allogeneic CD19-Directed CAR NK

  • Fludarabine, CyclophosphamideDrug

    For Lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]Time frame: The first 28 days after the first NKX019 dose
  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: From the first administration of NKX019 until the last administration of any study treatment + 30 days
  3. Incidence of clinically significant abnormalities in clinical laboratory assessments [Safety and Tolerability]Time frame: From the first NKX019 dose until the last follow up visit

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • Nkarta Investigational Site

    Little Rock, Arkansas · Recruiting

  • Nkarta Investigational Site

    Tustin, California · Recruiting

  • Nkarta Investigational Site

    Gainesville, Florida · Recruiting

  • Nkarta Investigational Site

    Miami, Florida · Withdrawn

  • Nkarta Investigational Site

    Plantation, Florida · Recruiting

  • Nkarta Investigational Site

    Tampa, Florida · Recruiting

  • Nkarta Investigational Site

    Atlanta, Georgia · Recruiting

  • Nkarta Investigational Site

    Chicago, Illinois · Recruiting

  • Nkarta Investigational Site

    New Orleans, Louisiana · Recruiting

  • Nkarta Investigational Site

    Worcester, Massachusetts · Recruiting

  • Nkarta Investigational Site

    Ann Arbor, Michigan · Recruiting

  • Nkarta Investigational Site

    Summit, New Jersey · Recruiting

  • Nkarta Investigational Site

    New York, New York · Recruiting

  • Nkarta Investigational Site

    Stony Brook, New York · Recruiting

  • Nkarta Investigational Site

    Syracuse, New York · Recruiting

  • Nkarta Investigational Site

    Dallas, Texas · Recruiting

  • Nkarta Investigational Site

    Houston, Texas · Recruiting

  • Nkarta Investigational Site

    Parkville, Victoria, Australia · Recruiting

  • Nkarta Investigational Site

    Manati, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.